News

[ad_1] Malaysian securities regulator charges Serba Dinamik, seeks arrest of CEO [ad_2] Source link

[ad_1] Share Market News Today | Sensex, Nifty, Share Prices LIVE: Domestic equity market benchmarks BSE Sensex and Nifty 50 were staring at a negative start on Wednesday, on the back of weak global cues. Nifty futures were trading 50 points or 0.3 per cent down at 17,213 on the Singaporean Exchange in the early trade. In the previous session, Sensex ended 477.24 points or 0.83 per cent higher at 57,897.48, while Nifty 50 index surged 147 points or 0.86 to settle at 17233.25. Asian peers were seen trading mixed in early trade as investors assessed the impact of the Omicron Covid variant. Japan’s Nikkei 225 slipped 0.82 per cent and the Topix index also declined 0.44 per cent. South Korea’s Kospi fell 0.75 per cent. In overnight trade on Wall Street, S&P 500 closed slightly lower. The Dow Jones Industrial Average rose 95.83 points, or 0.26%, the S&P 500 lost 4.84 points, or 0.10%, and the Nasdaq Composite dropped 89.54 points, or 0.56%. The country’s real gross domestic product (GDP) is likely to maintain a 9 pc growth rate in fiscal 2022 and 2023, amid concerns over the Omicron variant of COVID-19, says a report. The Indian economy grew at 8.4 per cent in the second quarter of the current fiscal, as against a growth of 20.1 per cent in the April-June quarter. [ad_2] Source link

[ad_1] Stock up on leggings with this great deal at Old Navy today! Today only, Old Navy has Girl’s Powersoft Leggings for just $10 and Women’s Powersoft Leggings for just $12! There are lots of colors to choose from. Choose free in-store pickup to avoid shipping costs. [ad_2] Source link

[ad_1] S&P 500 ends lower after four-day rally to record high [ad_2] Source link

[ad_1] The Central drug authority has granted approval to Serum Institute of India’s Covid-19 vaccine Covovax, Biological E’s jab Corbevax and anti-Covid pill Molnupiravir for restricted use in emergency situation. Union health minister Mansukh Mandaviya made the announcement in a series of tweets on Tuesday, a day after the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended granting emergency use authorisation (EUA) to Covovax and Corbevax with certain conditions. As many as 13 companies in the country will now manufacture Molnupiravir and it will be used for treatment of adult Covid-19 patients and those who have high risk of progression of the disease. With the latest approvals, the number of Covid vaccines that have received EUA in the country has increased to eight. Biological E’s Corbevax has been approved for patients 18 years and older. The vaccine is stored at 2-8˚C temperatures and comes as 0.5 ml single dose and 5 ml (10 doses) vial pack. Bio E has conducted phase I/II, II/III clinical trials of its Covid-19 vaccine in the country. Further, it has also conducted phase III active clinical trial to evaluate superiority against the Covishield vaccine. The Covovax vaccine from Serum has been approved for adults. It is a technology transfer of Novavax USA vaccine and a two-dose vaccine given on day 0 and 21. The vaccine is stored at 2-8˚C temperatures and presented as 0.5 ml single dose and 5 ml 10 doses vial pack. The European Medicines Agency has granted conditional approval to Novovax vaccine while Covovax has been granted emergency use listing (EUL) by WHO. Molnupiravir is an antiviral that inhibits SARS-CoV-2 replication by viral mutagenesis. The UK MHRA had on December 12 granted approval for Molnupiravir under special condition for treatment of mild-to-moderate Covid-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The USFDA granted EUA for Molnupiravir on December 23 for the treatment of mild-to-moderate coronavirus disease in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe Covid-19, including hospitalisation or death, and for whom alternative Covid-19 treatment options authorised by the FDA were not accessible or clinically appropriate. The CDSCO had received total 22 applications for manufacture and market of the drug Molnupiravir in the country. Of this, eight including five applicants of a consortium of 13 have submitted their clinical trial interim or complete reports. Dr Reddy’s, Natco, MSN, Hetero, Optimus, Aurobindo, Mylan, Strides, Emcure, Cipla, Sun Pharma, Torrent and BDR are the 13 companies which have been granted permission to manufacture and market Molnapiravir. The SEC has recommended grant of permission to manufacture and market the Molnupiravir 200 mg capsule with recommended dose of 800 mg twice daily for 5 days for treatment of adult patients with Covid-19, with SpO2 >93% and who have high risk of progression of the disease, including hospitalisation. The Molnupiravir drug has to be sold by retail only under prescription of medical specialists. [ad_2] Source link

[ad_1] These Brusheez Toothbrushes are so fun for kids! Today only (12/28), Zulily has the popular Brusheez Kids’ Electric Toothbrush on sale for $14.99! Plus, when you shop through our link, you will save an extra 10% off making them only $13.49! Choose from several different fun varieties! Brusheez sent us a toothbrush to try, and Kierstyn has been obsessed with it! She carries it around with her all the time. She is SO excited about her new toothbrush and it has really gotten her eager to get in the habit of brushing her teeth every day. She often asks to brush them on her own because she loves using it so much! Shipping starts at $5.99. But if you place one order today, the rest of your orders will ship for FREE through 11:59 p.m. PT tonight! [ad_2] Source link

[ad_1] Waymo and Geely's Zeekr partner to develop driverless taxis [ad_2] Source link

[ad_1] Hyderabad-based Biological E said on Tuesday that it would deliver the 300 million doses of the Covid-19 vaccine, Corbevax, as promised to the government of India. Corbevax is India’s first indigenously developed protein sub-unit vaccine against Covid-19. The company said it has reached production levels of 75 million doses per month at present and would make 100 plus million doses per month from February 2022.  The company said it would soon deliver more than one billion additional doses globally.Corbevax received the approval from the Drugs Controller General of India on Tuesday. The vaccine has been developed by Biological E in collaboration with Texas Children’s Hospital Centre for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine (Baylor) in Houston, Texas.Biological E’s Corbevax completed two Phase-III clinical trials involving more than 3,000 subjects between the ages of 18 and 80 at 33 study sites across India. The company said their Corbevax demonstrated superior immune response in comparison with Covishield when assessed for neutralising antibody (nAb) Geometric Mean Titers (GMT) against the ancestral-Wuhan strain and the globally dominant Delta variant.The  nAb GMT against the Wuhan strain  indicated vaccine effectiveness of  more than 90% for prevention of symptomatic infections while against the Delta strain, the vaccine showed effectiveness of above 80% for the prevention of symptomatic infections based on published studies. “While none of the subjects who took Corbevax or Covishield had serious adverse events, Corbevax had 50% fewer adverse events than Covishield,” Biological E said. There was only  30% drop in nAB GMt till six months second dose as compared to 80% drop observed with majority of the vaccines.Mahima Datla, managing director, Biological E, acknowledged the role of their collaborators and the Indian government’s advance commitment support for  scaling up and manufacture at such huge capacities.  The Covid Suraksha Programme had helped accelerate vaccine development and played a crucial role in the initial development, Datla said. This mechanism that was set up with the support of Department of Biotechnology  and Biotechnology Industry Research Assistance Council (BIRAC) allowed them to scale up to a capacity of about 1.2 billion doses per annum, Datla added. [ad_2] Source link

[ad_1] This article is part of our HousingWire 2022 forecast series. After the series wraps early next year, join us on February 8 for the HW+ Virtual 2022 Forecast Event. Bringing together some of the top economists and researchers in housing, the event will provide an in-depth look at the predictions for next year, along with a roundtable discussion on how these insights apply to your business. The event is exclusively for HW+ members, and you can go here to register. By the fall, real estate agents in Boise, Idaho were passing around a video they didn’t like but couldn’t resist watching. “Boise is in a full-fledged housing crash!” declared Nicholas Gerli, CEO of Reventure Consulting. Talking rapidly into the video frame, Gerli bandied about a Florida Atlantic University report that Boise homes purchased are overvalued by 80%, and city residents ought to rent. The managing partner of ACCEL Realty Partners in Boise, Steve Caporale, said that the video gave him pause, especially since, “The market has been softening a bit.” But — in the same beat — Caporale added, “There is still a massive influx of buyers, and I am not seeing a significant drop in demand.” The broker’s cautious optimism is echoed nationally. U.S. real estate in 2022 may see challenges to its biggest enterprises, including the National Association of Realtors and Zillow, and shifting adjustments to how work is done amid the coronavirus pandemic. But home sales or real estate prices dropping may not be in the cards. “We just went through one of the biggest housing booms in modern history,” said Jonathan Miller, a real estate appraiser at Miller Samuel who also produces housing market reports for Douglas Elliman. “What we’re starting to see is more of a cooling or a plateauing than a market correction.” How big? 2021 is projected to have the most home sales since the 2006 housing bubble, with the U.S. on pace for 6.29 million homes sold at the end of September, according to National Association of Realtors data. Moreover, 2021 was a historic year for home prices. By July, the median home price escalated to $362,800, up 15% from December 2020’s $309,000 median home price, which itself was up 15% from December 2019, according to NAR figures. July was the plateau. By September, home prices dipped to $352,800, per the trade group’s figures. “The frenetic pace of the market has eased,” Miller said. “There’s buyer fatigue and real questions about affordability.” Slowing down the pace, Miller said, is the average interest rate on a 30-year-fixed rate mortgage — 3.09% by late October, according to Freddie Mac, after it hovered below 3% for most of 2021. Another factor is that real estate has partly returned to seasonal cycles, including a back-to-school lull. “We’ve seen the fall be more of a normal fall,” said Mike Golden, co-CEO of @properties. Rising interest rates. Seasonal ebbs and flows. These are significant changes for real estate professionals but possible to plan for. Less predictable is what is next for 12 metropolitan areas that, per NAR numbers, really boomed, seeing an over 30% price climb from the second quarter 2020 to quarter two in 2021. This includes Boise, which saw a 41% jump in median sales price during the period studied. But since June 30, prices have leveled off to about $530,000, according to data provided by Stacie Herrig, who is a Boise-based agent at Fathom Realty. “While it’s still a strong seller’s market, there just aren’t the up-to-20 offers coming in on homes anymore,” Herrig said. “Sellers aren’t getting a free puppy or pony with their buyer’s offers any longer.” “Some sort of balance or price stability is crucial,” Herrig added. Herrig hopes national homebuilders recently entering Idaho, including Shea and Lennar, can address inventory shortfalls. As agents prepare for the housing market’s next turn, they face choices about how to best do their jobs. Some heads of brokerages see a thru line from pre- and (hopefully, eventually) post-pandemic real estate. “Obviously when COVID-19 hit we had to adapt tremendously, but I don’t think the home buying process has really changed,” Golden said. The Chicago-based brokerage has added five offices amid the pandemic, swelling its physical locales to past 40. “Agents still need a space to work from,” Golden said. Lake Norman Realty, a brokerage headquartered in Cornelius, North Carolina, has also maintained its physical presence. “We anticipate more brokers to return to their office desks as COVID numbers continue to decrease in our region,” said Abigail Jennings, president of Lake Norman Realty. “I haven’t had any brokers permanently working from home, and nobody’s ready to give up their desk yet.” Other brokers, like Teri Pacitto of Sotheby’s Realty, said that while offices will remain, rituals “like long mid-day Wednesday meetings and breakfast being brought in” are thing of the past. U.S. real estate, however, is not known for its change. The formula for the buyers and sellers agent splitting up a commission — and charging a total of 5-6% of the home listing price — has been around since before the First World War. The Justice Department is broadly investigating NAR, stating that American home buyers and sellers spend $85 billion a year on commissions. DOJ has investigated NAR many times before. But NAR’s antagonism to federal antitrust officials — stemming from DOJ’s July 1 withdrawal from a consent decree between the parties — is unprecedented. “This has set the groundwork for several years of the DOJ and NAR not working together,” said Ken H. Johnson, a real estate professor at Florida Atlantic University. “NAR could never trust this administration’s DOJ again.” This article was first featured in the Dec/Jan HousingWire Magazine issue. To read the full issue, go here. The post What’s next after a historic housing boom? appeared first on HousingWire. [ad_2] Source link

[ad_1] “I can’t do this. It’s too much. I’m scared.” I lay awake in bed pretty much all night long the first night Baby D arrived. I felt completely overwhelmed and in over my head. When they told us he had Down syndrome and a cleft lip (they didn’t realize he had a cleft palate, too) + a feeding tube, I expected an 8-month-old baby that was somewhat delayed. I didn’t expect him to show up as a tiny malnourished infant that was just 11 pounds, in 0-3 month clothes, and non-responsive. I knew he needed a lot of medical care and DCS didn’t know contact info/names for any of his doctors or specialists, I had no clue what I was doing — and Jesse was out of town that week! In this last podcast episode of the year, Jesse and I sat down and talked about what we learned in 2021 and the entire theme was how this sweet boy has completely changed our lives. I could recount story after story of specific ways that God has showed up and answered prayers, helped us track down all the specialists in record time, brought just the right medical professionals into our lives at the right time, protected Baby D in the process of us not knowing so much, and has been so faithful to carry us through many scary moments and nights. Not only was our faith and trust in the Lord stretched and strengthened in big ways as we saw God show up, but like Jesse said so eloquently (and it brought tears to my eyes): “When Baby D came to us, he needed multiple surgeries. But what we didn’t know was that God was going to use his little life to perform surgery on our hearts.” Truly, this little boy has completely changed all of us in profound ways. And he’s been one of the greatest gifts we’ve ever experienced as a family. I struggle to put into words just how deeply this boy has captivated and changed our hearts forever! We could have never dreamed what 2021 had in store for our family, but God writes the best stories! In this episode, Jesse and I also talk about a few other things we learned in 2021, a book I’ve been reading for a long time and finally finished, an app Jesse loves, and a snack I’ve been enjoying. We also tease a big episode we have coming at the beginning of 2022. You won’t want to miss it! Thank you so much for all of you who regularly listen to the podcast each week. We are so grateful for each and every one of you and are looking forward to what 2022 brings! In This Episode [00:34] – Last night was a bit of an unexpected night, but it reminded me of how easy it is to take things for granted. [02:13] – Speaking of perspective, today we are going to be talking about what we learned in 2021. [03:05] – A weather app that has been so help! [06:00] – Nuts and vegetables, how can you go wrong? [06:42] – I finished a book I’ve been slowly reading for a long time! [09:16] – So let’s talk about what we learned in 2021. [12:04] – It’s okay to have seasons where you’re not as goal-driven and goal-orientated, but I also realized that I missed the focus that more goal-setting brings. [14:55] – 2020 taught us all that, what we think life is going to look like can be completely upended. [15:32] – Jesse shares his two takeaways from 2021. [17:54] – A big part of our story this year was saying yes to Baby D. [22:16] – It was such a faith-building experience for both of us. [24:29] – In the process of Baby D’s surgeries, our hearts have been repaired as well. [26:04] – Thank you so much for joining us this year! Links & Resources Books The Mystery of Providence by John Flavel Don’t Miss Out: Daring to Believe Life is Better with the Holy Spirit by Jeannie Cunnion Special Mentions Storm Shield, weather app Skinny Dipped Cashews Other Links Love-Centered Parenting 10 Days to Be a Happier Mom Sign up for the Hot Deals Email List MoneySavingMom.com My Instagram account (I’d love for you to follow me there! I usually hop on at least a few times per day and share behind-the-scenes photos and videos, my grocery store hauls, funny stories, or just anything I’m pondering or would like your advice or feedback on!) Have feedback on the show or suggestions for future episodes or topics? Send me an email: crystal @ moneysavingmom.com [ad_2] Source link